Raymond James analyst Dane Leone upgraded Regeneron to Market Perform from Underperform.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
- Regeneron announces FDA approval of Evkeeza for young children
- Regeneron, Sanofi announce EC approval of Dupixent
- Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis